Osteosarcoma phenotype is inhibited by 3,4-methylenedioxy-β- nitrostyrene

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Messerschmitt, Patrick J ^a   Rettew, Ashley N ^a   Schroeder, Nicholas O ^a   Brookover, Robert E ^a   Jakatdar, Avanti P ^a   Getty, Patrick J ^a   Greenfield, Edward M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXY BETA NITROSTYRENE; MESSENGER RNA; PROTEIN TYROSINE KINASE; STYRENE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CELL SPECIFICITY; COLONY FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; METASTASIS; MOLECULAR LIBRARY; OSTEOBLAST; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SRC HOMOLOGY DOMAIN;

EID: 84862285953     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/479712     Document Type: Article

References (45)

1. Surveillance E., End Results (SEER) Program, SEER Stat Database: Incidence-SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2007 Sub (19732005 varying)Linked to County AttributesTotal U.S., 19692005 2008 National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
2. Bielack S., Kempf-Bielack B., Delling G., Exner G., Flege S., Helmke K., Kotz R., Salzer-Kuntschik M., Werner M., Winkelmann W., Zoubek A., Jurgens H., Winkler K., Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols Journal of Clinical Oncology 2002 20 776 790 (Pubitemid 34111386)
3. Davis A. M., Bell R. S., Goodwin P. J., Prognostic factors in osteosarcoma: a critical review Journal of Clinical Oncology 1994 12 2 423 431 (Pubitemid 24056419)
4. Messerschmitt P. J., Garcia R. M., Abdul-Karim F. W., Greenfield E. M., Getty P. J., Osteosarcoma Journal of the American Academy of Orthopaedic Surgeons 2009 17 8 515 527
5. Meyers P. A., Schwartz C. L., Krailo M., Kleinerman E. S., Betcher D., Bernstein M. L., Conrad E., Ferguson W., Gebhardt M., Goorin A. M., Harris M. B., Healey J., Huvos A., Link M., Montebello J., Nadel H., Nieder M., Sato J., Siegal G., Weiner M., Wells R., Wold L., Womer R., Grier H., Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate Journal of Clinical Oncology 2005 23 9 2004 2011 (Pubitemid 46211380)
6. Chou A. J., Kleinerman E. S., Krailo M. D., Chen Z., Betcher D. L., Healey J. H., Conrad E. U., Nieder M. L., Weiner M. A., Wells R. J., Womer R. B., Meyers P. A., Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Cancer 2009 115 22 5339 5348
7. Meyers P. A., Schwartz C. L., Krailo M. D., Healey J. H., Bernstein M. L., Betcher D., Ferguson W. S., Gebhardt M. C., Goorin A. M., Harris M., Kleinerman E., Link M. P., Nadel H., Nieder M., Siegal G. P., Weiner M. A., Wells R. J., Womer R. B., Grier H. E., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survivala report from the children's oncology group Journal of Clinical Oncology 2008 26 4 633 638 (Pubitemid 351264359)
8. Kaap S., Quentin I., Tamiru D., Shaheen M., Eger K., Steinfelder H. J., Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds Biochemical Pharmacology 2003 65 4 603 610 (Pubitemid 36144246)
9. Kim J. H., Kim J. H., Lee G. E., Lee J. E., Chung I. K., Potent inhibition of human telomerase by nitrostyrene derivatives Molecular Pharmacology 2003 63 5 1117 1124 (Pubitemid 36529930)
10. Mohan R., Rastogi N., Namboothiri I. N. N., Mobin S. M., Panda D., Synthesis and evaluation of -hydroxymethylated conjugated nitroalkenes for their anticancer activity: inhibition of cell proliferation by targeting microtubules Bioorganic Medicinal Chemistry 2006 14 23 8073 8085 (Pubitemid 44584691)
11. Wang W. Y., Hsieh P. W., Wu Y. C., Wu C. C., Synthesis and pharmacological evaluation of novel -nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity Biochemical Pharmacology 2007 74 4 601 611
12. Wang W. Y., Wu Y. C., Wu C. C., Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy- -nitrostyrene, a novel tyrosine kinase inhibitor Molecular Pharmacology 2006 70 4 1380 1389
13. Levitzki A., Mishani E., Tyrphostins and other tyrosine kinase inhibitors Annual Review of Biochemistry 2006 75 93 109 (Pubitemid 44118027)
14. Messerschmitt P. J., Rettew A. N., Brookover R. E., Garcia R. M., Getty P. J., Greenfield E. M., Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro Clinical Orthopaedics and Related Research 2008 466 9 2168 2175
15. Hughes D. P. M., Thomas D. G., Giordano T. J., McDonagh K. T., Baker L. H., Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition Pediatric Blood and Cancer 2006 46 5 614 623
16. Coopman P. J., Mueller S. C., The Syk tyrosine kinase: a new negative regulator in tumor growth and progression Cancer Letters 2006 241 2 159 173 (Pubitemid 44163045)
17. Rezzonico R., Schmid-Alliana A., Romey G., Bourget-Ponzio I., Breuil V., Breittmayer V., Tartare-Deckert S., Rossi B., Schmid-Antomarchi H., Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells Journal of Bone and Mineral Research 2002 17 5 869 878 (Pubitemid 34441904)
18. Yanagi S., Inatome R., Takano T., Yamamura H., Syk expression and novel function in a wide variety of tissues Biochemical and Biophysical Research Communications 2001 288 3 495 498 (Pubitemid 33030056)
19. Craxton A., Jiang A., Kurosaki T., Clark E. A., Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt Journal of Biological Chemistry 1999 274 43 30644 30650
20. Stewart Z. A., Pietenpol J. A., Syk: a new player in the field of breast cancer Breast Cancer Research 2001 3 1 5 7 (Pubitemid 32223644)
21. Bradshaw J. M., The Src, Syk, and Tec family kinases: distinct types of molecular switches Cellular Signalling 2010 22 8 1175 1184
22. Turner M., Schweighoffer E., Colucci F., Di Santo J. P., Tybulewicz V. L., Tyrosine kinase SYK: essential functions for immunoreceptor signalling Immunology Today 2000 21 3 148 154 (Pubitemid 30122705)
23. Alvarez R. H., Kantarjian H. M., Cortes J. E., The role of Src in solid and hematologic malignancies: development of new-generation src inhibitors Cancer 2006 107 8 1918 1929 (Pubitemid 44582963)
24. Hingorani P., Zhang W., Gorlick R., Kolb E. A., Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo Clinical Cancer Research 2009 15 10 3416 3422
25. Shor A. C., Keschman E. A., Lee F. Y., Muro-Cacho C., Letson G. D., Trent J. C., Pledger W. J., Jove R., Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival Cancer Research 2007 67 6 2800 2808 (Pubitemid 46548969)
26. Worth L. L., Jia S. F., Zhou Z., Chen L., Kleinerman E. S., Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases Clinical Cancer Research 2000 6 9 3713 3718
27. Luu H. H., Kang Q., Jong K. P., Si W., Luo Q., Jiang W., Yin H., Montag A. G., Simon M. A., Peabody T. D., Haydon R. C., Rinker-Schaeffer C. W., He T. C., An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis Clinical and Experimental Metastasis 2005 22 4 319 329 (Pubitemid 41374288)
28. Duan X., Jia S. F., Zhou Z., Langley R. R., Bolontrade M. F., Kleinerman E. S., Association of v 3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells Clinical and Experimental Metastasis 2005 21 8 747 753 (Pubitemid 40755014)
29. Jia S. F., Worth L. L., Kleinerman E. S., A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies Clinical and Experimental Metastasis 1999 17 6 501 506 (Pubitemid 30182744)
30. Blake R. A., Broome M. A., Liu X., Wu J., Gishizky M., Sun L., Courtneidge S. A., SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling Molecular and Cellular Biology 2000 20 23 9018 9027 (Pubitemid 32245931)
31. Lai J. Y. Q., Cox P. J., Patel R., Sadiq S., Aldous D. J., Thurairatnam S., Smith K., Wheeler D., Jagpal S., Parveen S., Fenton G., Harrison T. K. P., McCarthy C., Bamborough P., Potent small molecule inhibitors of spleen tyrosine kinase (Syk) Bioorganic Medicinal Chemistry Letters 2003 13 18 3111 3114 (Pubitemid 36993648)
32. Hisamichi H., Naito R., Toyoshima A., Kawano N., Ichikawa A., Orita A., Orita M., Hamada N., Takeuchi M., Ohta M., Tsukamoto S. I., Synthetic studies on novel Syk inhibitors. Part 1: synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives Bioorganic Medicinal Chemistry 2005 13 16 4936 4951 (Pubitemid 40943518)
33. Yamamoto N., Takeshita K., Shichijo M., Kokubo T., Sato M., Nakashima K., Ishimori M., Nagai H., Li Y. F., Yura T., Bacon K. B., The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c] pyrimidin-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents Journal of Pharmacology and Experimental Therapeutics 2003 306 3 1174 1181 (Pubitemid 37025329)
34. Betapudi V., Licate L. S., Egelhoff T. T., Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration Cancer Research 2006 66 9 4725 4733
35. Edin M. L., Howe A. K., Juliano R. L., Inhibition of PKA blocks fibroblast migration in response to growth factors Experimental Cell Research 2001 270 2 214 222 (Pubitemid 33030160)
36. Dai J. C., He P., Chen X., Greenfield E. M., TNF and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics Bone 2006 38 4 509 520
37. Bain J., Plater L., Elliott M., Shpiro N., Hastie C. J., Mclauchlan H., Klevernic I., Arthur J. S. C., Alessi D. R., Cohen P., The selectivity of protein kinase inhibitors: a further update Biochemical Journal 2007 408 3 297 315
38. Rettew A. N., Getty P. J., Greenfield E. M., Novel receptor tyrosine kinases in osteosarcoma identified by phosphoproteomic and functional genomic screening Proceedings of the 101st Annual Meeting of the American Association for Cancer Research April 2010 Washington, DC, USA
39. Milhazes N., Calheiros R., Marques M. P. M., Garrido J., Cordeiro M. N. D. S., Rodrigues C., Quinteira S., Novais C., Peixe L., Borges F., -Nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study Bioorganic Medicinal Chemistry 2006 14 12 4078 4088
40. Pettit R. K., Pettit G. R., Hamel E., Hogan F., Moser B. R., Wolf S., Pon S., Chapuis J. C., Schmidt J. M., E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory -E-nitrostyrenes Bioorganic Medicinal Chemistry 2009 17 18 6606 6612
41. McNamara Y. M., Cloonan S. M., Knox A. J. S., Keating J. J., Butler S. G., Peters G. H., Meegan M. J., Williams D. C., Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents Bioorganic Medicinal Chemistry 2011 19 3 1328 1348
42. Walsh A. H., Cheng A., Honkanen R. E., Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A FEBS Letters 1997 416 3 230 234 (Pubitemid 27475370)
43. Werner J. M., Eger K., Jrgen Steinfelder H., Comparison of the rapid pro-apoptotic effect of trans- -nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells Apoptosis 2007 12 1 235 246 (Pubitemid 46009516)
44. Deng X., Ito T., Carr B., Mumby M., May W. S. Jr., Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A Journal of Biological Chemistry 1998 273 51 34157 34163 (Pubitemid 29008888)
45. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L. C., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W., Specific association of human telomerase activity with immortal cells and cancer Science 1994 266 5193 2011 2015